Similarly, G2/M arrest was achieved in GPER-positive human HCC1806 TNBC cells following treatment with a GPER-targeted proteolytic targeting chimera (PROTAC), while cell cycle blockade did not occur in GPER-low human MDA-MB-231 breast cancer cells [78]. This evidence concerns the gene GPER1 and breast cancer.